All In Biotech

NDA 021361 · Salix Pharms

Xifaxan

Rifaximin · Oral · Rifamycin Antibacterial

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Oct 19, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

May 25, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

212

56 Phase 3, 22 recruiting

FAERS reports

21,335

16,688 serious, 6,241 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2025.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated for: • Treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older. ( 1.1 ) • Reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. ( 1.2 ) • Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. ( 1.3 ) Limitations of Use TD: Should not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. ( 1.1, 5.1 ) 1.1 Travelers’ Diarrhea XIFAXAN is indicated for the treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adults and pediatric patients 12 years of age and older. Limitations of Use XIFAXAN should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli [see Warnings and Precautions ( 5.1 ), Clinical Pharmacology ( 12.4 ), Clinical Studies ( 14.1 )]. 1.2 Hepatic Encephalopathy XIFAXAN is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. In the placebo-controlled trial of XIFAXAN for HE, 91% of the patients were using lactulose...

Mechanism: Rifaximin is an antibacterial drug [see Clinical Pharmacology ( 12.4 )].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 27, 2015 Supplement 12 · Efficacy · priority review LabelLetter
  • May 25, 2004 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewLetter
2 products under this application
  • XIFAXAN · RIFAXIMIN 550MG · TABLET, ORAL · Prescription · TE AB
  • XIFAXAN · RIFAXIMIN 200MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rifaximin" as an intervention, any sponsor and status, largest first.

All 212 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death4,264
  • hospitalisation1,954
  • diarrhoea1,258
  • off label use1,176
  • therapy interrupted1,176
  • ammonia increased862
  • nausea854
  • hepatic encephalopathy836
  • fatigue815
  • drug ineffective752
  • confusional state733
  • insurance issue729

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
200542
200671
200748
200831
200946
201081
2011115
2012177
2013186
2014294
2015904
20161,653
20172,331
20181,477
20191,813
20201,958
20211,931
20221,771
20232,023
20241,640
20251,328
20261,404

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xifaxan (Rifaximin)

2024 spending

$1.16B

Beneficiaries

104,805

416,690 claims

Per beneficiary

$11,050

$54.19 per unit

View as table
YearSpending
2020$844,562,189
2021$890,298,769
2022$969,541,694
2023$1,090,110,101
2024$1,158,111,409

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 325 on PubMed

Sponsor: Salix Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.